Cureus | CD248 expression on mesenchymal stromal cells is required for post-natal and infection-dependent thymus remodelling and regeneration
SIQ
-
Rate article
What's this?
Research Article

CD248 expression on mesenchymal stromal cells is required for post-natal and infection-dependent thymus remodelling and regeneration

Siân Lax, Ewan A. Ross, Andrea White, Jennifer L. Marshall, William E. Jenkinson, Clare M. Isacke, David L. Huso, Adam F. Cunningham, Graham Anderson, Christopher D. Buckley

Published: July 20, 2012

DOI: 10.1016/j.fob.2012.07.003

License: © 2012 Published by Elsevier B.V. on behalf of Federation of European Biochemical Societies.2012Federation of European Biochemical SocietiesThis is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works License, which permits non- commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

The role of mesenchymal stromal cells (MSCs) in regulating immune responses in the thymus is currently unclear. Here we report the existence and role of a MSC population in the thymus that expresses the pericyte and MSC marker CD248 (endosialin). We show using a CD248-deficient mouse model, that CD248 expression on these cells is required for full post-natal thymus development and regeneration post-Salmonella infection. In CD248−/− mice the thymus is hypocellular and regeneration is poorer, with significant loss of all thymocyte populations. This identifies the requirement of CD248 to maintain optimal thymic cellularity post-partum and infection.Highlights▸ The mesenchymal stromal cell marker CD248 is expressed in the thymus on pericytes. ▸ Genetic deletion of CD248 prevents full post-natal development of the thymus. ▸ Genetic deletion of CD248 prevents infection-dependent regeneration following thymic atrophy. ▸ CD248 regulates blood endothelial vessel formation in the thymus.


View Full Article  
Share

What's SIQ™?

Scholarly Impact Quotient™ (SIQ™) is our unique post-publication peer review rating process. SIQ™ assesses article importance and quality by embracing the collective intelligence of the Cureus community-at-large. All registered users are invited to contribute to the SIQ™ of any published article. (Authors cannot rate their own articles.)

High ratings should be reserved for work that is truly groundbreaking in its respective field. Anything above 5 should be considered above average. While all registered Cureus users can rate any published article, the opinion of domain experts is weighted appreciably more than that of non-specialists. An article’s SIQ™ will appear alongside the article after being rated twice and is recalculated with each additional rating.

Visit our SIQ™ page to find out more.

Close

Scholarly Impact Quotient™ (SIQ™)

Scholarly Impact Quotient™ (SIQ™) is our unique post-publication peer review rating process. SIQ™ assesses article importance and quality by embracing the collective intelligence of the Cureus community-at-large. All registered users are invited to contribute to the SIQ™ of any published article. (Authors cannot rate their own articles.)

Already have an account? Sign in.

Cancel Join Now

Share this article with your colleagues. Each email address must be separated by a comma.

Later

Download Cureus Media Kit